production.
8-10
The association between high IL-10 levels and fatality of to BMT and at days 46 and 100 after BMT. However, in patients with severe complications additional samples septic shock was explained by the fact that IL-10 might not be able to inhibit production of proinflammatory cytokines, were drawn at individual points in time. Prior to BMT, IL-10 serum levels were not detectable in 24/24 patients. while suppressing T cell reactions which might otherwise have supported pathogen elimination. In this study the role Post-BMT, 11 patients developed elevated IL-10 levels, of these eight died of complications (DOC), whereas of IL-10 in patients after BMT was investigated under the hypothesis that in post-BMT patients, as in sepsis, only one of 15 patients with undetectable IL-10 died of complications, indicating that high IL-10 levels were sigincreased IL-10 might be correlated to poor outcome. IL-10 serum levels correlated with the clinical course of the nificantly correlated with severe life-threatening complications ( 2 , P Ͻ 0.01). To determine the pathomechandisease, the severity of acute phase reactions and macrophage activation. ism and role of the increased IL-10 levels, they were correlated to the respective NP and CRP serum concentrations. CRP and NP concentrations were found sigPatients and methods nificantly elevated in patients with detectable IL-10, indicating a severe acute phase reaction associated with Patients macrophage activation. In conclusion, high IL-10 serum levels in patients after BMT were significantly associaTwenty-six children and adolescents were enrolled into this study. Patients' ages ranged from 4.0 to 22.4 years (median: ted with fatal outcome. Since IL-10 is a strong suppressor of T cell immunity, high IL-10 production in 13.4 years). The male to female ratio was 18 to 8. Patients had previously been treated for ALL (12), AML (7), CML patients with severe complications such as septic shock or GVHD Ͼgrade II after BMT might lead to functional (2) , NHL (3) and Ewing's sarcoma (2). Five patients had received an allogeneic transplant from a matched-related immunodeficiency contributing to the poor prognosis of these patients.
donor, four patients had been transplanted with bone marrow from an haploidentical related donor and seven patients Keywords: sepsis; bone marrow transplantation; interleukin 10; neopterin had had unrelated donors. In addition, 10 patients had received autologous bone marrow or peripheral blood stem cell transplants. Blood was drawn from patients prior to BMT and at days 46 and 100 after BMT. However, in IL-10 is a potent macrophage and T cell-deactivating patients with multi-organ failure (MOF) additional blood cytokine, leading to a significant suppression of cytokine samples were taken during these complications. 
Results

Cytokine analysis
To determine the role of IL-10 in patients after BMT, ILConcentrations of IL-10 were assessed by commercially 10 serum levels were correlated with the clinical course of available ultrasensitive ELISA kits (BioSource, Camarillo, the patients. Prior to BMT ('day 0') serum levels of IL-CA, USA) as described previously. 3 The lowest concen-10 were undetectable in all patients. Post-BMT 11 patients tration detected by this assay was 200 fg/ml. developed detectable IL-10 at various points in time. Of these, eight patients died of complications within 1-14 (median 4) days after an elevated IL-10 had been found.
Neopterin (NP) determination
The three surviving patients with elevated IL-10 serum levSerum neopterin levels were measured by HPLC. Briefly, els presented with acute GVHD grade II or severe CMV 200 l samples or standards were added to a mobile phase infection. One patient received systemic IL-2 treatment at containing 0.1 m KH 2 PO 4 , (Merck, Darmstadt, Germany), the time of IL-10 determination. In 15/26 patients IL-10 0.005 m octansulfonic acid (Fluka, Bux, Switzerland; pH remained undetectable throughout the observation period. was adjusted to 3.0 with 1 N HCl) and 50 l of 3.4 m Of these, only one succumbed to complications. The last HClO 4 . After vortexing the mixtures for 30 s, samples were IL-10 measurement in this patient had been done 21 days centrifuged at 11 500 r.p.m. for 5 min. Supernatants (50 l) prior to his death so that an increased IL-10 may have been were applied to a HPLC (Li-Chros-Pher 100 RP 8E; missed. Thus, we found detectable IL-10 levels to be sigMerck). Neopterin concentrations were determined at Ex nificantly correlated with DOC ( Figure 1 ; Table 2 ; 2 , wavelength of 360 nm compared with Em wavelength of P Ͻ 0.01). 430 nm.
Next, the mechanism of in vivo IL-10 production was investigated. It was found that in patients with detectable IL-10, CRP levels (median: 8.57 mg/dl) were significantly CRP determination elevated as compared to patients with undetectable IL-10 (median: 0 mg/l; Figure 2 , Wilcoxon test, P Ͻ 0.001). CRP values were determined by particle-enhanced immunonephelometry. 40 l serum were applied to a fully autoThus, in our patient population the IL-10 serum levels were associated with a severe acute phase reaction. matic nephelometer (Behringwerke, Marburg, Germany).
Since IL-10 is produced by both T cells and macrophages, [11] [12] [13] we determined the serum concentrations of neopterin as an indicator of macrophage activation.
14- 16 It was shown that high IL-10 levels were positively correlated with increased neopterin levels ( Figure 3 , Wilcoxon test, P Ͻ 0.01). Thus, increased IL-10 levels in post-BMT patients might be produced by macrophage activation during an acute phase reaction.
Discussion
After bone marrow transplantation, different parts of the immune system recover at different times. One of the earliest detectable functions is the production of macrophagederived cytokines. 17 Increased macrophage activation might view is presented by the observation that increased IL-10 levels were associated with a significantly increased production of neopterin, a protein released from macrophages Table 2 Clinical course of patients with elevated IL-10 levels upon activation.
14-16
In patients after BMT, elevated neopterin and an abnor-
No. IL-10 level Complications Status
mal monocyte activation has been observed from the time of engraftment until 6 weeks after BMT. 14 Since macro- Correlation between IL-10 and neopterin serum levels in patients after BMT. Neopterin serum levels were determined in 26 patients Figure 2 Correlation between IL-10 and CRP levels in patients after BMT. CRP serum levels were determined in 26 patients after BMT on after BMT on the same days that IL-10 was measured. Elevated neopterin was significantly associated with detectable IL-10 (Wilcoxon test, the same days that IL-10 was measured. Elevated CRP was significantly associated with detectable IL-10 (Wilcoxon test, P Ͻ 0.001).
P Ͻ 0.01). 
